The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Safety and efficacy of linvoseltamab for patients with R/R multiple myeloma
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses data from a Phase I/II trial (NCT03761108) investigating the BCMAxCD3 bispecific antibody, linvoseltamab, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Richter discusses the dose-response curve of this agent, and how further adjustment of dosage and treatment scheduling could improve efficacy and tolerability. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
